Shared insight from a panel of key opinion leaders on the evolving treatment landscape of myeloproliferative neoplasms and improvements in care.
EP. 1: Overview on Essential Thrombocythemia and Polycythemia Vera Management
Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.
EP. 2: Role of Symptom Burden in Thrombocythemia and Polycythemia Vera
Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.
EP. 3: Novel Therapy in Myelofibrosis: Momelotinib
Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.
EP. 4: Therapy in Myelofibrosis: Pacritinib
Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.
EP. 5: Myelofibrosis: Nuancing the Potential of Disease Modification
A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.
EP. 6: Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies
Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.
EP. 7: What is the Role of Transplant in Managing Patients With Myelofibrosis?
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
EP. 8: Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.
EP. 9: An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation
A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.
EP. 10: Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms
Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.
EP. 11: Myeloproliferative Neoplasm Management: Future Directions in Care
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer
A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer
FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC